Zhixiang Jintai: Silewemi monoclonal antibody injection receives drug clinical trial approval letter.

On the evening of July 29, Zhixiang Jintai announced that the company received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's investigational product, Solawemab monoclonal antibody injection, has been approved for clinical trial application for passive immunization indications in children and adolescents aged 2 to 18 suspected of exposure to rabies virus.